← Back to Search

Other

KIN-2787 + Binimetinib for Solid Tumors with BRAF and/or NRAS Mutations

Phase 1
Waitlist Available
Research Sponsored by Pierre Fabre Medicament
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Are you currently not pregnant or lactating or breastfeeding?
Do you currently not have a medical condition preventing you from taking medications by mouth?
Timeline
Screening 3 weeks
Treatment Varies
Follow Up initiation of study drug until disease progression (up to approximately 36 months)
Awards & highlights
No Placebo-Only Group

Summary

This trial is testing a new drug called KIN-2787 to see if it is safe and effective for adults with advanced cancers that have specific genetic mutations. The drug works by blocking proteins that help cancer cells grow.

Eligible Conditions
  • Melanoma
  • Lung Cancer
  • Solid Tumors

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
You are not currently pregnant or breastfeeding.
Select...
You are able to take medications orally without any medical condition preventing you from doing so.
Select...
Do you have a cancerous tumor that has spread to other parts of your body, such as lung cancer or skin cancer?
Select...
Your cancer has a specific genetic mutation called BRAF or NRAS.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~initiation of study drug until disease progression (up to approximately 36 months)
This trial's timeline: 3 weeks for screening, Varies for treatment, and initiation of study drug until disease progression (up to approximately 36 months) for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
In Part B (Dose Expansion) - duration of overall response (DOR).
In Part B (Dose Expansion) - objective response rate (ORR) using RECIST v1.1.
Part A1 Dose escalation monotherapy
+1 more

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

4Treatment groups
Experimental Treatment
Group I: Dose Expansion Monotherapy (Part B1)Experimental Treatment1 Intervention
Dose expansion evaluating the recommended phase 2 dose (RP2D) of KIN-2787
Group II: Dose Escalation Monotherapy (Part A1)Experimental Treatment1 Intervention
Dose escalation of KIN-2787
Group III: Dose Escalation Combination therapy (Part B2)Experimental Treatment1 Intervention
Dose expansion evaluating the recommended phase 2 dose (RP2D) of KIN-2787 and binimetinib
Group IV: Dose Escalation Combination therapy (Part A2)Experimental Treatment1 Intervention
Dose escalation of KIN-2787 and binimetinib

Find a Location

Who is running the clinical trial?

Pierre Fabre MedicamentLead Sponsor
80 Previous Clinical Trials
19,846 Total Patients Enrolled
9 Trials studying Melanoma
1,372 Patients Enrolled for Melanoma
Kinnate BiopharmaLead Sponsor
1 Previous Clinical Trials
54 Total Patients Enrolled
CLaire FABRE, MDStudy ChairPierre Fabre Laboratories

Media Library

KIN-2787 (Other) Clinical Trial Eligibility Overview. Trial Name: NCT04913285 — Phase 1
Melanoma Research Study Groups: Dose Expansion Monotherapy (Part B1), Dose Escalation Combination therapy (Part B2), Dose Escalation Monotherapy (Part A1), Dose Escalation Combination therapy (Part A2)
Melanoma Clinical Trial 2023: KIN-2787 Highlights & Side Effects. Trial Name: NCT04913285 — Phase 1
KIN-2787 (Other) 2023 Treatment Timeline for Medical Study. Trial Name: NCT04913285 — Phase 1
Melanoma Patient Testimony for trial: Trial Name: NCT04913285 — Phase 1
~94 spots leftby Nov 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top